BDX's Rotarex Atherectomy System Wins FDA Indication Expansion Approval

by Vandana Singh, Benzinga Editor

October 6, 2021 8:22 AM | 1 min read |

Becton, Dickinson And Co BDX has received FDA 510(k) clearance for expanded indications for the Rotarex Atherectomy System.
Related: BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance.
The Rotarex Atherectomy System is a rotational excisional device built to remove and aspirate varying lesion morphologies, including plaque and thrombus in the peripheral arteries.
The Rotarex System, already cleared for use in native arterial vessels, now has the expanded indications to treat within peripheral arteries fitted with stents, stent-grafts, and native or artificial bypasses.
Related content: Benzinga's Full FDA Calendar.
Price Action: BDX stock closed 1.08% higher at $243.06 on Tuesday.

Posted In: News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.